S-1

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Teysuno (Nordic Group B.V.): advanced gastric cancer in combination with cisplatin;... (EU)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

Also in development:Colorectal Cancer · Phase 3 · investigational in the USGastric Cancer · Phase 3 · investigational in the US

Also approved (2)
EU
  • Teysuno (Nordic Group B.V.): advanced gastric cancer in combination with cisplatin; metastatic colorectal cancer, as monotherapy or with oxaliplatin or irinotecan, with or without bevacizumab, when another fluoropyrimidine cannot be continued due to hand-foot syndrome or cardiovascular toxicity
Product first approved 2011EMA
JP
  • TS-1 (tegafur, gimeracil, oteracil potassium; Taiho Pharmaceutical): non-small cell lung cancer; also gastric, colorectal, head and neck, inoperable or recurrent breast, pancreatic and biliary tract cancers
taiho.co.jp

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (46)
Colorectal Cancer
NCT01918852 · Dutch Colorectal Cancer Group
2013-12 – 2018-03 · Colorectal Cancer, Metastases
What this study did
NCT00660894 · Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
2008-04 – 2015-07 · Colorectal Cancer
What this study did
NCT00677443 · Samsung Medical Center
2008-06 – 2011-01 · Colorectal Cancer
What this study did
Gastric Cancer
NCT07522151 · Shanghai Shengdi Pharmaceutical Co., Ltd
2026-05-07 – 2034-02 · Locally Advanced Gastric or Gastroesophageal Junction Cancer
What this study did
NCT07366528 · Ruijin Hospital
2025-12-15 – 2030-10-31 · Gastric Cancer (GC), Adjuvant Chemotherapy, Stage 3 Cancer, Docetaxel, Oxaliplatin
What this study did
NCT04483076 · Chinese PLA General Hospital
2021-01-13 – 2028-12 · Gastric Cancer, Chemotherapy Effect
What this study did
NCT04997837 · Fudan University
2021-07-21 – 2027-10-21 · Gastric Cancer
What this study did
NCT03941561 · Fudan University
2019-01-01 – 2027-05-01 · Gastric Cancer
What this study did
NCT05593458 · Zhejiang University
2023-03-01 – 2026-12 · Locally Advanced Gastric Carcinoma
What this study did
NCT03961867 · Sixth Affiliated Hospital, Sun Yat-sen University
2020-09-15 – 2025-09 · Gastric Cancer
What this study did
NCT04135781 · Zhejiang Cancer Hospital
2020-03-01 – 2024-10-31 · Stomach Cancer
What this study did
NCT02338518 · Jinling Hospital, China
2015-01-04 – 2023-10 · Stomach Neoplasms, Gastric Cancer
What this study did
NCT03801668 · Huazhong University of Science and Technology
2019-03-08 – 2023-03-31 · Gastric Cancer
What this study did
NCT02736552 · Fudan University
2016-03 – 2023-03 · Gastric Cancer
What this study did
NCT01515748 · Sanofi
2011-12-30 – 2021-12-13 · Gastric Cancer
What this study did
NCT02867839 · Peking University Cancer Hospital & Institute
2017-04-24 – 2021-09-01 · Gastric Cancer
What this study did
NCT03475615 · Fudan University
2018-03-16 – 2020-12-31 · Gastric Cancer, Stomach Neoplasms
What this study did
NCT02114359 · Seoul National University Hospital
2014-02 – 2020-02 · Gastric Cancer
What this study did
NCT01824459 · Sun Yat-sen University
2013-04 – 2018-12-01 · Gastric Cancer
What this study did
NCT01795027 · Sun Yat-sen University
2011-09 – 2018-06 · Gastric Cancer
What this study did
NCT01583361 · Lin Chen
2012-03 – 2017-01 · Gastric Adenocarcinoma
What this study did
NCT01671449 · Min-Hee Ryu
2012-12 – 2015-10 · Gastric Cancer
What this study did
NCT01285557 · Taiho Oncology, Inc.
2011-04-14 – 2014-08-15 · Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction
What this study did
NCT00915382 · Asan Medical Center
2009-01 – 2013-05 · Advanced Gastric Cancer
What this study did
NCT01198392 · Sun Yat-sen University
2008-09 – 2011-12 · Gastric Cancer
What this study did
NCT00287768 · Japan Clinical Cancer Research Organization
2006-03 – 2010-10 · Gastric Cancer
What this study did
NCT00182611 · Kyoto University
2004-04 – 2008-11 · Gastric Cancer
What this study did
NCT00202969 · Taiho Pharmaceutical Co., Ltd.
2005-07 – 2007-06 · Gastric Cancer
What this study did
NCT00142350 · Japan Clinical Oncology Group
2000-11 – 2007-01 · Gastric Cancer
What this study did
Non-Small Cell Lung Cancer
Other / comorbidity
NCT06571461 · CSPC Ouyi Pharmaceutical Co., Ltd.
2024-09 – 2029-03 · Pancreatic Cancer
What this study did
NCT05813015 · Zhejiang University
2023-01-28 – 2026-12-31 · Locally Advanced Gastric Adenocarcinoma, Chemotherapy Effect
What this study did
NCT05771480 · AstraZeneca
2023-08-16 – 2026-09-17 · Biliary Tract Cancer
What this study did
NCT03708536 · Fujian Cancer Hospital
2018-11 – 2022-11 · Colorectal Adenocarcinoma
What this study did
NCT02813967 · Zhejiang Cancer Hospital
2016-06 – 2020-08 · Esophageal Cancer, Chemoradiation
What this study did
NCT02677597 · Fudan University
2016-01 – 2019-01 · Esophageal Squamous Cell Carcinoma
What this study did
NCT02182778 · Kansai Hepatobiliary Oncology Group
2014-07-09 – 2018-04-16 · Biliary Tract Cancer
What this study did
NCT00770874 · Taiho Pharmaceutical Co., Ltd.
2008-09 – 2016-04 · Cervical Cancer
What this study did
NCT00869635 · Asan Medical Center
2009-02 – 2013-08 · Cholangiocarcinoma
What this study did
NCT00336947 · Yokohama City University
2006-04 – 2012-03 · Head and Neck Cancer
What this study did
NCT00602745 · Sanofi
2008-02 – 2010-03 · Pancreatic Neoplasm, Neoplasm Metastasis
What this study did
Phase 2/3 (10)
Gastric Cancer
NCT03607656 · Shanghai University of Traditional Chinese Medicine
2018-06-08 – 2023-11-30 · Gastric Cancer Stage IIIB, Gastric Cancer Stage IIIC
What this study did
NCT02423278 · First Affiliated Hospital, Sun Yat-Sen University
2010-01 – 2020-12 · Gastric Cancer, Surgery, Effects of Chemotherapy
What this study did
NCT02979691 · Chinese Academy of Medical Sciences
2016-10 – 2020-04 · Esophagus Cancer, Esophagogastric Junction Cancer, Radiotherapy; Complications, Chemoradiation
What this study did
NCT02817425 · LanZhou University
2013-05 – 2019-05 · Gastric Cancer
What this study did
NCT00503321 · Eastern Network of Cancer Immunological Therapy, Japan
2006-10 – 2011-08 · Gastric Cancer
What this study did
NCT00639327 · Japan Clinical Cancer Research Organization
2008-03 – 2011-06 · Gastric Cancer
What this study did
Other / comorbidity
NCT06662877 · Sun Yat-sen University
2024-11-25 – 2029-09-01 · Biliary Tract Cancer, Second Line Treatment, Chemotherapy, Tyrosine Kinase Inhibitor
What this study did
NCT05955157 · University of Malaya
2023-01-03 – 2025-06 · Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor
What this study did
NCT01704690 · Peking University
2012-08 – 2017-03 · Esophageal Cancer
What this study did
Phase 2 (234)
Colorectal Cancer
NCT02487992 · The First People's Hospital of Changzhou
2015-07 – 2045-07 · Colorectal Neoplasms
What this study did
NCT07243938 · Tao Zhang
2026-01-15 – 2031-06-01 · Locally Advanced Rectal Cancer (LARC), Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (mCRC), Neoadjuvant Therapy
What this study did
NCT06746545 · Fujian Cancer Hospital
2025-02-01 – 2027-02-01 · Colorectal Cancer
What this study did
NCT03843853 · The First Affiliated Hospital with Nanjing Medical University
2019-05-01 – 2022-05-01 · Colorectal Neoplasms
What this study did
NCT03397199 · Henan Cancer Hospital
2018-01-09 – 2021-03 · Colorectal Cancer
What this study did
NCT02618356 · Fudan University
2015-12-25 – 2017-11 · Metastatic Colon Cancer
What this study did
NCT03517618 · TTY Biopharm
2014-07-05 – 2015-06-18 · Metastatic Colorectal Cancer
What this study did
NCT01929421 · Gachon University Gil Medical Center
2009-12 – 2014-12 · Advanced Colorectal Cancer
What this study did
NCT00721916 · Taiho Pharmaceutical Co., Ltd.
2008-07 – 2012-05 · Colorectal Cancer
What this study did
NCT00677144 · Hallym University Medical Center
2008-04 – 2012-04 · Colorectal Neoplasm
What this study did
NCT01193452 · Fudan University
2010-08 – 2012-02 · Colorectal Cancer
What this study did
NCT00891332 · Taiho Pharmaceutical Co., Ltd.
2008-10 – 2011-11 · Colorectal Cancer
What this study did
NCT00569699 · Taiho Pharmaceutical Co., Ltd.
2007-10 – 2011-03 · Colorectal Cancer
What this study did
NCT00506571 · National Cancer Center, Korea
2007-07 – 2010-06 · Colorecal Neoplasms, Secondary
What this study did
NCT00974389 · Osaka Medical College
2009-07 – 2010-06 · Colorectal Cancer
What this study did
NCT00569790 · Taiho Pharmaceutical Co., Ltd.
2007-10 – 2010-03 · Colorectal Cancer
What this study did
NCT00569335 · Taiho Pharmaceutical Co., Ltd.
2007-10 – 2010-03 · Colorectal, Cancer
What this study did
NCT00209651 · Hokkaido Gastrointestinal Cancer Study Group
2004-01 – 2007-12 · Colorectal Cancer
What this study did
Gastric Cancer
NCT07492615 · Fudan University
2026-01-29 – 2033-02-20 · Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
What this study did
NCT07007182 · Jinbo Yue
2025-10-01 – 2030-10-01 · Gastric Adenocarcinoma, Stomach Neoplasms
What this study did
NCT07464756 · The First Affiliated Hospital with Nanjing Medical University
2026-04-03 – 2030-07-31 · Gastric Adenocarcinoma
What this study did
NCT07018063 · zhoujing
2025-10-01 – 2030-06-01 · Gastric (Cardia, Body) Cancer, Stomach Adenocarcinoma, Locally Advanced
What this study did
NCT06881017 · China Medical University, China
2025-05-01 – 2029-11-01 · Gastric Cancer, HER2 + Gastric Cancer, CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, PD-L1 Positive
What this study did
NCT07556640 · Ruijin Hospital
2026-04-17 – 2029-04-30 · Gastric Cancer Stage IV, Peritoneal Metastases From Gastric Cancer, Gastric or Esophagogastric Junction Adenocarcinoma
What this study did
NCT07515625 · Fudan University
2026-04-01 – 2029-04-01 · Gastric Cancer (GC), AFP Gastric or Gastroesophageal Junction Adenocarcinoma
What this study did
NCT06238167 · First Affiliated Hospital of Wenzhou Medical University
2024-04-01 – 2028-12-31 · Gastric Cancer
What this study did
NCT07685704 · Zhifeng Zhao, PhD
2026-07 – 2028-12 · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, HER2-positive Gastric Cancer
What this study did
NCT07194005 · Fudan University
2025-09-04 – 2028-09-30 · Gastric Cancer
What this study did
NCT06487429 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2024-05-08 – 2028-05-31 · Gastric Cancer
What this study did
NCT07621484 · Shanghai Changzheng Hospital
2026-07-13 – 2028-05-09 · Locally Advanced Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT06385873 · The First Affiliated Hospital with Nanjing Medical University
2024-05-01 – 2028-05-01 · Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
What this study did
NCT06555471 · The First Affiliated Hospital with Nanjing Medical University
2024-08-06 – 2027-12-31 · Gastric Cancer
What this study did
NCT07304258 · Hebei Medical University
2025-12-12 – 2027-12-31 · Gastric Cancer Peritoneal Metastases
What this study did
NCT06693128 · Ruijin Hospital
2024-11-21 – 2027-12-31 · Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
What this study did
NCT07374250 · Sichuan University
2026-02-01 – 2027-12-31 · Gastric Cancer, RCT
What this study did
NCT06730373 · Qilu Hospital of Shandong University
2024-10-17 – 2027-12-31 · HER2-positive Gastric Cancer, Metastatic Gastric Cancer, Unresectable Gastric Carcinoma
What this study did
NCT06451211 · Sun Yat-sen University
2023-05-17 – 2027-11 · Stomach Neoplasms, Gastric Cancer, Linitis Plastica of Stomach
What this study did
NCT05524974 · Fujian Medical University
2022-09-01 – 2027-09-01 · Locally Advanced Gastric Cancer
What this study did
NCT05687357 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
2023-03-15 – 2027-08-31 · Gastric Cancer, Gastroesophageal-junction Cancer
What this study did
NCT06510010 · Sixth Affiliated Hospital, Sun Yat-sen University
2024-12-31 – 2027-07-31 · Chemotherapy Effect
What this study did
NCT06213519 · Sichuan University
2024-02-20 – 2027-06-30 · Peritoneal Metastases, Gastric Cancer
What this study did
NCT06454435 · Tianjin Medical University Cancer Institute and Hospital
2024-06 – 2027-06 · Gastric Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT06519591 · Ruijin Hospital
2025-02-25 – 2027-01 · Gastric Cancer Stage IV, Peritoneal Metastases
What this study did
NCT06341595 · The First Affiliated Hospital with Nanjing Medical University
2024-04-01 – 2026-12-31 · Gastric Cancer, Gastric Cancer Metastatic to Regional Lymph Nodes
What this study did
NCT06939452 · Yongxu Jia
2023-06-07 – 2026-06-01 · Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
What this study did
NCT06487715 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2024-03-01 – 2026-03-01 · Gastric Cancer Peritoneal Metastases
What this study did
NCT04999332 · National Cheng-Kung University Hospital
2021-12-10 – 2025-12-31 · Gastric Cancer, Gastric Adenocarcinoma, Effects of Chemotherapy, Toxicity Due to Chemotherapy
What this study did
NCT05586061 · Qilu Hospital of Shandong University
2023-02-10 – 2025-12-31 · HER2-positive Gastric Cancer
What this study did
NCT05853172 · Tianjin Medical University Cancer Institute and Hospital
2023-03-21 – 2025-12-21 · Gastric Cancer
What this study did
Phase 1/2 (27)
Colorectal Cancer
NCT00524706 · Shizuoka Cancer Center
2007-08 – 2011-04 · Colorectal Cancer
What this study did
NCT01110941 · Shen Lin
2009-09 – 2010-10 · Colorectal Cancer
What this study did
Gastric Cancer
NCT07025889 · Ruijin Hospital
2025-06-02 – 2028-06 · Gastric Cancer
What this study did
NCT06732856 · Asan Medical Center
2025-04-04 – 2027-12-31 · Stomach Neoplasm, Gastric (Stomach) Cancer
What this study did
NCT04781413 · Ruijin Hospital
2021-03-01 – 2024-03-01 · Stage IIIC Gastric Cancer
What this study did
NCT01783951 · Capital Medical University
2013-02-01 – 2018-06-01 · Gastric Cancer
What this study did
NCT02317471 · Chinese PLA General Hospital
2014-11 – 2017-12 · Gastric Carcinoma
What this study did
NCT01106066 · Samsung Medical Center
2009-03 – 2012-11 · Phase I: To Determine the Maximum Tolerated Dose (MTD), Phase II: To Assess the Pathologic CR Rate and Feasibility Following Neoadjuvant Chemoradiation Therapy With S1/Oxaliplatin
What this study did
NCT00209729 · Hokkaido Gastrointestinal Cancer Study Group
2005-04 – 2010-03 · Gastric Cancer
What this study did
NCT00072787 · Taiho Oncology, Inc.
2003-10 – 2006-05 · Gastric Cancer
What this study did
NCT00209638 · Hokkaido Gastrointestinal Cancer Study Group
2000-05 – 2003-04 · Gastric Cancer
What this study did
Non-Small Cell Lung Cancer
NCT07551778 · BOE Technology Group Co., Ltd.
2026-08 – 2029-04 · NSCLC (Advanced Non-small Cell Lung Cancer), Colorectal Cancer, Advanced Solid Tumors, Advanced Hepatocellular Carcinoma (HCC), GC/GEJC
What this study did
NCT00874328 · National Cancer Center, Korea
2008-10 – 2012-12 · Advanced Non-Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT06038461 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2023-09-15 – 2028-09-15 · Neuroendocrine Tumors
What this study did
NCT07727993 · Ting Liu
2026-08-01 – 2027-12-31 · Gastric or Gastroesophageal Junction Adenocarcinoma, Propranolol, SOX Chemotherapy, Toripalimab
What this study did
NCT05403242 · Chinese PLA General Hospital
2022-09-20 – 2026-09 · Advanced Gastroesophageal Adenocarcinoma
What this study did
NCT05218889 · Chinese PLA General Hospital
2021-08-04 – 2025-06 · Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreas Cancer, Pancreatic Neoplasms
What this study did
NCT04662112 · Asan Medical Center
2021-06-15 – 2024-12-30 · Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
What this study did
NCT03991104 · Zhejiang Provincial People's Hospital
2019-05-01 – 2023-12-31 · Esophageal Cancer
What this study did
NCT03654612 · China International Medical Foundation
2018-10-16 – 2021-09-01 · Head and Neck Cancer
What this study did
NCT02564367 · AIO-Studien-gGmbH
2015-10-06 – 2020-03-06 · Adenocarcinoma,Stomach, Adenocarcinoma, Esophagogastric Junction
What this study did
NCT01781520 · Capital Medical University
2013-06-01 – 2017-06-13 · Pancreatic Cancer
What this study did
NCT01227239 · Japan Clinical Cancer Research Organization
2010-09 – 2016-08 · Rectal Carcinoma
What this study did
NCT01415713 · National Health Research Institutes, Taiwan
2012-03 – 2016-04 · Metastatic Pancreatic Adenocarcinoma
What this study did
NCT01284413 · Kansai Hepatobiliary Oncology Group
2010-12 – 2013-08 · Biliary Tract Cancer
What this study did
NCT00209677 · Hokkaido Gastrointestinal Cancer Study Group
2004-12 – 2007-12 · Pancreatic Cancer
What this study did
NCT00980382 · National Cancer Center, Korea
2004-09 – 2007-08 · Stomach Neoplasms
What this study did
Phase 1 (31)
Colorectal Cancer
NCT03380689 · Fujian Cancer Hospital
2018-01-05 – 2019-01-05 · Metastatic Colorectal Cancer
What this study did
NCT00641615 · Kazuhiko Yoshimatsu
2007-05 – 2011-07 · Colorectal Cancer
What this study did
Gastric Cancer
NCT07923396 · Ruijin Hospital
2026-11 – 2028-12 · Gastric Cancer (GC)
What this study did
NCT03977220 · Shanghai Zhongshan Hospital
2020-01-01 – 2023-12-31 · Gastric Cancer
What this study did
NCT03162510 · National Health Research Institutes, Taiwan
2018-06-26 – 2022-01-31 · Gastric Cancer in Situ, Pancreatic Cancers, Biliary Cancers
What this study did
NCT03276156 · Zhejiang Cancer Hospital
2016-02-23 – 2018-02-22 · Gastric Cancer
What this study did
NCT00553696 · Pfizer
2007-11 – 2014-03 · Stomach Neoplasms
What this study did
NCT01291407 · Chinese Academy of Medical Sciences
2010-11 – 2013-09 · Gastrointestinal Neoplasms, Gastric Cancer
What this study did
NCT00960349 · AstraZeneca
2009-08 – 2011-03 · Gastric Cancer
What this study did
Non-Small Cell Lung Cancer
Other / comorbidity
NCT07356466 · Fujian Medical University
2025-05-01 – 2030-04-30 · Gastric (Stomach) Cancer
What this study did
NCT06229496 · Chang Gung Memorial Hospital
2023-08-01 – 2028-12-31 · Metastatic Pancreatic Adenocarcinoma
What this study did
NCT02347904 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2014-12 – 2019-11 · Esophageal Cancer
What this study did
NCT02387138 · Institut du Cancer de Montpellier - Val d'Aurelle
2014-04 – 2018-09 · Digestive Cancer
What this study did
NCT02454062 · Taiho Oncology, Inc.
2013-03 – 2017-09-30 · Advanced Solid Tumors
What this study did
NCT01713387 · Kansai Hepatobiliary Oncology Group
2012-04 – 2017-03 · Biliary Tract Cancer
What this study did
NCT01610479 · Taiho Pharmaceutical Co., Ltd.
2012-06 – 2017-02 · Advanced Solid Tumors
What this study did
NCT01946646 · National Taiwan University Hospital
2013-10 – 2017-01 · Metastatic Pancreatic Cancer
What this study did
NCT02359058 · Eli Lilly and Company
2015-02 – 2016-11 · Stomach Neoplasms
What this study did
NCT01128998 · National Health Research Institutes, Taiwan
2009-11 – 2015-10 · Advanced Solid Tumors
What this study did
NCT02867397 · Disphar International B.V.
2012-01 – 2015-08 · Patients With Advanced or Metastatic Solid Tumors
What this study did
NCT01693445 · Hallym University Medical Center
2012-06 – 2014-08 · Gastrointestinal Neoplasms
What this study did
NCT01291615 · Kansai Hepatobiliary Oncology Group
2010-12 – 2013-05 · Biliary Tract Cancer
What this study did
NCT01175447 · Zhejiang Cancer Hospital
2010-02 – 2011-12 · Esophageal Cancer
What this study did
NCT00479076 · Sanofi
2007-03 – 2011-01 · Neoplasms
What this study did
NCT01175460 · Zhejiang Cancer Hospital
2010-01 – 2011-01 · Esophageal Cancer
What this study did
NCT00398307 · Taiho Oncology, Inc.
2006-02 – 2010-09 · Renal Impairment
What this study did
NCT00506207 · National Cancer Center, Korea
2006-09 – 2009-12 · Colorectal Neoplasm, Gastric Neoplasm, Secondary
What this study did
NCT00398424 · Taiho Oncology, Inc.
2006-02 – 2009-03 · Impaired Hepatic Function
What this study did
NCT00400023 · Taiho Oncology, Inc.
2006-09 – 2007-05 · Tumors
What this study did
Phase 4 (6)
Gastric Cancer
NCT07944664 · Rui-hua Xu, MD, PhD
2026-01-13 – 2028-12 · Gastric Cancer (GC), Gastroesophageal Junction (GEJ) Adenocarcinoma
What this study did
NCT06169410 · Yang Jianjun, PhD
2023-12-30 – 2025-12-31 · Advanced Gastric Cancer
What this study did
Other / comorbidity
NCT06779318 · The First Affiliated Hospital with Nanjing Medical University
2025-07 – 2028-07 · Pancreatic Cancer, Postoperative Adjuvant Therapy, Maintenance Therapy
What this study did
NCT04217096 · Fudan University
2020-01-01 – 2023-03-31 · Advanced Pancreatic Cancer
What this study did
NCT01849380 · Shandong University
2013-06 – 2018-06 · Breast Neoplasms, Neoadjuvant Therapy
What this study did
NCT01997957 · Zhu Xu
2013-10 – 2016-09 · Hepatocellular Carcinoma
What this study did
Early phase / not applicable (10)
Gastric Cancer
NCT04675866 · Henan Cancer Hospital
2020-08-17 – 2023-12-31 · Advanced Gastric Adenocarcinoma
What this study did
Other / comorbidity
NCT07892573 · Ningbo Medical Center Lihuili Hospital
2026-10-07 – 2028-02-01 · Pancreatic Cancer
What this study did
NCT04047953 · Peking University Cancer Hospital & Institute
2019-09-10 – 2026-11 · Gastric Adenocarcinoma
What this study did
NCT06171321 · Shanghai East Hospital
2023-12 – 2026-04-01 · Biliary Tract Cancer
What this study did
NCT04518800 · Chinese PLA General Hospital
2020-08-18 – 2022-02-18 · PEG-rhG-CSF, Pancreatic Cancer
What this study did
NCT04239001 · CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
2020-02 – 2021-06 · Advanced Pancreatic Cancer
What this study did
NCT02704143 · Changhai Hospital
2016-02 – 2020-05 · Pancreatic Cancer
What this study did
NCT02592538 · First People's Hospital of Hangzhou
2015-12 – 2019-03 · Cholangiocarcinoma
What this study did
NCT02734680 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2016-02 – 2019-02 · Pancreatic Cancer
What this study did
NCT01364376 · Zhejiang University
2011-06 – 2016-08 · Stomach Neoplasms
What this study did
Used as active comparator (3)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (2)
Gastric Cancer
NCT02322593 · Taiho Pharmaceutical Co., Ltd.
2014-12 – 2020-05 · Gastric Cancer
What this study did
Other / comorbidity
NCT06194734 · Beijing Konruns Pharmaceutical Co., Ltd.
2024-02-05 – 2027-12-30 · Esophageal Squamous Cell Carcinoma
What this study did
Phase 2 (1)
Other / comorbidity
NCT07772557 · The First Affiliated Hospital with Nanjing Medical University
2026-09-01 – 2032-01-20 · Gastric or Gastroesophageal Junction Adenocarcinoma
What this study did
Appears in other studies (15)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (8)
Gastric Cancer
NCT07818070 · Ono Pharmaceutical Co., Ltd.
2027-02 – 2031-01 · Gastric Cancer, Esophagogastric Junction Cancer, Esophageal Adenocarcinoma
What this study did
NCT03013010 · Shanghai Cancer Hospital, China
2016-12 – 2024-12-05 · Stomach Neoplasm, GastroEsophageal Cancer, Adenocarcinoma, Locally Advanced Cancer, Chemoradiation
What this study did
NCT03006705 · Ono Pharmaceutical Co., Ltd.
2017-01-31 – 2023-03-31 · Gastric Cancer
What this study did
NCT00687843 · Tokyo Metropolitan Oncology Group
2008-06 – 2016-03 · Gastric Cancer
What this study did
NCT00216034 · Hokuriku-Kinki Immunochemotherapy Study Group
2005-03 – 2016-02 · Gastric Cancer
What this study did
Other / comorbidity
NCT06109779 · AstraZeneca
2023-12-04 – 2030-05-03 · Biliary Tract Cancer
What this study did
NCT03615326 · Merck Sharp & Dohme LLC
2018-10-05 – 2025-11-12 · Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT02319187 · Chinese Academy of Medical Sciences
2014-12 – 2017-06 · Esophageal Neoplasms
What this study did
Phase 2/3 (1)
Gastric Cancer
NCT04208347 · Ruijin Hospital
2019-12-18 – 2027-12 · Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
What this study did
Phase 2 (5)
Colorectal Cancer
NCT02688023 · Chinese Academy of Medical Sciences
2014-03 – 2019-12 · Colorectal Cancer
What this study did
Gastric Cancer
NCT05769725 · RenJi Hospital
2023-03-01 – 2026-03-31 · Serplulimab,Gastric Cancer, Adjuvant Therapy
What this study did
Other / comorbidity
NCT07870798 · The First Affiliated Hospital with Nanjing Medical University
2026-10-15 – 2028-12-31 · Gastric or Gastroesophageal Junction Adenocarcinoma
What this study did
NCT03002831 · Henan Cancer Hospital
2016-11 – 2019-10 · Advanced Cancer
What this study did
Early phase / not applicable (1)
Gastric Cancer
NCT04886193 · Guangdong Provincial Hospital of Traditional Chinese Medicine
2021-04-16 – 2023-05 · Chemotherapy, Gastric Cancer
What this study did

Competitive landscape

This drug's own stage for Colorectal Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
S-1: this drugPhase 3Small moleculeThymidylate synthase (via 5-FU, released from tegafur) and dihydropyrimidine dehydrogenase (inhibited by gimeracil)not yet gradedNo reviewed efficacy summary in this indication
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AtezolizumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor Inhibitornot yet gradedNo reviewed efficacy summary in this indication
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Capecitabine
ApprovedUS marketing discontinued
Small moleculeFluoropyrimidine (antimetabolite)not yet gradedNo reviewed efficacy summary in this indication
EncorafenibApprovedSmall moleculeBRAF V600Enot yet gradedNo reviewed efficacy summary in this indication
Fruquintinib (Fruzaqla / Elunate)ApprovedSmall moleculeVEGFR1/2/3Reliable signal
NCT04322539: Median overall survival 7.4 months with fruquintinib (95% CI 6.7 to 8.2) vs 4.8 months with placebo (95% CI 4.0 to 5.8); stratified HR 0.662 (95% CI 0.549 to 0.800), p<.001
NCT02314819: Median overall survival 9.3 months with fruquintinib (95% CI 8.2 to 10.5) vs 6.6 months with placebo (95% CI 5.9 to 8.1); HR 0.65 (95% CI 0.51 to 0.83), P<.001 (published analysis)
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistnot yet gradedNo reviewed efficacy summary in this indication
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1Weak signalNo reviewed efficacy summary in this indication
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Weak signal
NCT02460198: Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor (Up to approximately 48 months): Cohort A - Pembrolizumab 200 mg 32.8 Percentage of participants (95% CI 21.3 to 46) | Cohort B - Pembrolizumab 200 mg 34.9 Percentage of participants (95% CI 23.3 to 48)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT01183780: Overall Survival (OS) (Randomization to Date of Death from Any Cause Up to 39.36 Months): Ramucirumab + FOLFIRI 13.3 months (95% CI 12.4 to 14.5) | Placebo + FOLFIRI 11.7 months (95% CI 10.8 to 12.7)
RegorafenibApprovedSmall moleculeMulti-kinase inhibitor (VEGFR/PDGFR/KIT)Reliable signal
NCT01584830: Overall survival: hazard ratio 0·55 regorafenib vs placebo (median 8·8 months vs 6·3 months; one-sided p=0·00016)
SotorasibApprovedSmall moleculeKRAS G12Cnot yet gradedNo reviewed efficacy summary in this indication
TucatinibApprovedSmall moleculeHER2Partial signal
NCT03043313: Confirmed Objective Response Rate (cORR) Per RECIST v1.1 Per Blinded Independent Central Review (BICR) in Pooled Cohorts A+B (Up to 46.6 months): Tucatinib+Trastuzumab (Cohorts A+B) 39.3 Percentage of Participants (95% CI 28.8 to 50.5)
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AmivantamabPhase 3Multispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Anbenitamab RepodatecanPhase 3Antibody–drug conjugateHER2 (biparatopic — extracellular domains II and IV)not yet gradedNo reviewed efficacy summary in this indication
BecotatugPhase 3Monoclonal antibodyEGFRnot yet gradedNo reviewed efficacy summary in this indication
BotensilimabPhase 3Monoclonal antibodyCTLA-4not yet gradedNo reviewed efficacy summary in this indication
ChidamidePhase 3Small moleculeHDACnot yet gradedNo reviewed efficacy summary in this indication
HLX04 (Hanbeitai)Phase 3Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
IBI363Phase 3Multispecific antibodyPD-1 x IL-2Rα (IL2RA)not yet gradedNo reviewed efficacy summary in this indication
INCA33890Phase 3Multispecific antibodyTGF-βR2 and PD-1 (conditional bispecific)not yet gradedNo reviewed efficacy summary in this indication
PF-08634404Phase 3Multispecific antibodyPD-1 + VEGFnot yet gradedNo reviewed efficacy summary in this indication
Telisotuzumab AdizutecanPhase 3Antibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Trastuzumab BrengitecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
ZanzalintinibPhase 3Small moleculeVEGFR2; MET; AXL; MER; TYRO3not yet gradedNo reviewed efficacy summary in this indication
N-DihydrogalactochitosanPhase 2/3PolysaccharideSTING and inflammasome pathwaysnot yet gradedNo reviewed efficacy summary in this indication
DSP107Phase 2Protein / enzyme therapeuticSIRP-alpha/4-1BBL fusion proteinnot yet gradedNo reviewed efficacy summary in this indication
IBI305Phase 2Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
SirexatamabPhase 2Monoclonal antibodyDKK1 (Dickkopf-1)not yet gradedNo reviewed efficacy summary in this indication
A2B530Phase 1/2Cell therapyCEA / carcinoembryonic antigen (activator) / HLA-A*02 (blocker)not yet gradedNo reviewed efficacy summary in this indication
NC410
Phase 1/2(overall)
Protein / enzyme therapeuticCollagen (LAIR-1 ligands)not yet gradedNo reviewed efficacy summary in this indication
BBO-10203Phase 1Small moleculeRAS:PI3Kα protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
KRAS-Specific Autologous TCR-T Cell
Phase 1(overall)
Cell therapyKRAS G12V presented on HLA-A*11:01not yet gradedNo reviewed efficacy summary in this indication
LY01008Phase 1Monoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LY4066434
Phase 1(overall)
Small moleculePan-KRASnot yet gradedNo reviewed efficacy summary in this indication
PalupiprantPhase 1Small moleculeEP4Weak signalNo reviewed efficacy summary in this indication
PF-07934040
Phase 1(overall)
Small moleculePan-KRASnot yet gradedNo reviewed efficacy summary in this indication
Tusamitamab SonditecanPhase 1Antibody–drug conjugateCEACAM5not yet gradedNo reviewed efficacy summary in this indication
PI3Kalpha Precision Therapy
—(overall)
Small molecule—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(61 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow S-1 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (10)
December 2026 (10)
Phase 2Gastric CancerRecruiting
Est. primary completion 2026-12-28 · NCT06510010 · CT.gov ↗
What to watch
Phase 2Biliary Tract CancerActive not recruiting
Est. primary completion 2026-12-30 · NCT06490107 · CT.gov ↗
What to watch
Phase 2Intrahepatic CholangiocarcinomaRecruiting
Est. primary completion 2026-12-30 · NCT06664021 · CT.gov ↗
What to watch
Phase 2Gastric CancerNot yet recruiting
Est. primary completion 2026-12-31 · NCT06238167 · CT.gov ↗
What to watch
Phase 2Locally Advanced Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT06187597 · CT.gov ↗
What to watch
Phase 2Gastric CancerRecruiting
Est. primary completion 2026-12-31 · NCT06555471 · CT.gov ↗
What to watch
Phase 2Gastric CancerNot yet recruiting
Est. primary completion 2026-12-31 · NCT07304258 · CT.gov ↗
What to watch
Phase 2Gastric CancerRecruiting
Est. primary completion 2026-12-31 · NCT06730373 · CT.gov ↗
What to watch
Phase 2Gastric AdenocarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT07867392 · CT.gov ↗
What to watch
Phase 3Locally Advanced Gastric Adenocarcinoma, Chemotherapy EffectRecruiting
Est. primary completion 2026-12-31 · NCT05813015 · CT.gov ↗
What to watch
2027 (23)
January 2027 (2)
Phase 2Gastric CancerRecruiting
Est. primary completion 2027-01 · NCT06519591 · CT.gov ↗
What to watch
Phase 2Recurrent or Metastatic Nasopharyngeal CarcinomaRecruiting
Est. primary completion 2027-01-30 · NCT07070479 · CT.gov ↗
What to watch
February 2027 (1)
Phase 2Gastric CancerRecruiting
Est. primary completion 2027-02-28 · NCT05687357 · CT.gov ↗
What to watch
March 2027 (1)
Phase 2Efficacy and SafetyNot yet recruiting
Est. primary completion 2027-03-01 · NCT06383078 · CT.gov ↗
What to watch
April 2027 (1)
Phase 1Gastric (Stomach) CancerEnrolling by invitation
Est. primary completion 2027-04-30 · NCT07356466 · CT.gov ↗
What to watch
May 2027 (2)
Phase 2Gastric CancerNot yet recruiting
Est. primary completion 2027-05-01 · NCT06385873 · CT.gov ↗
What to watch
Phase 2Gastric CancerNot yet recruiting
Est. primary completion 2027-05-30 · NCT06213519 · CT.gov ↗
What to watch
June 2027 (2)
Phase 1/2Gastric or Gastroesophageal Junction Adenocarcinoma, Propranolol, SOX Chemotherapy, ToripalimabNot yet recruiting
Est. primary completion 2027-06-30 · NCT07727993 · CT.gov ↗
What to watch
Phase 2Gastric CancerRecruiting
Est. primary completion 2027-06-30 · NCT05184803 · CT.gov ↗
What to watch
July 2027 (3)
Phase 1/2Gastric CancerRecruiting
Est. primary completion 2027-07 · NCT07025889 · CT.gov ↗
What to watch
Phase 4Pancreatic Cancer, Postoperative Adjuvant Therapy, Maintenance TherapyNot yet recruiting
Est. primary completion 2027-07 · NCT06779318 · CT.gov ↗
What to watch
Phase 3Gastric CancerRecruiting
Est. primary completion 2027-07-21 · NCT04997837 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2Metastatic Pancreatic Ductal AdenocarcinomaNot yet recruiting
Est. primary completion 2027-08-01 · NCT07733050 · CT.gov ↗
What to watch
September 2027 (3)
Phase 2Gastroesophageal Junction Adenocarcinoma, Gastric AdenocarcinomaActive not recruiting
Est. primary completion 2027-09 · NCT07776639 · CT.gov ↗
What to watch
Phase 1/2Neuroendocrine TumorsRecruiting
Est. primary completion 2027-09-15 · NCT06038461 · CT.gov ↗
What to watch
Early phase / not applicablePancreatic CancerRecruiting
Est. primary completion 2027-09-30 · NCT07892573 · CT.gov ↗
What to watch
December 2027 (7)
Phase 1Gastric CancerNot yet recruiting
Est. primary completion 2027-12 · NCT07923396 · CT.gov ↗
What to watch
Phase 2Gastric CancerNot yet recruiting
Est. primary completion 2027-12-30 · NCT07018063 · CT.gov ↗
What to watch
Phase 1Metastatic Pancreatic AdenocarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT06229496 · CT.gov ↗
What to watch
Phase 1/2Gastric CancerRecruiting
Est. primary completion 2027-12-31 · NCT06732856 · CT.gov ↗
What to watch
Phase 2Pan-tumorRecruiting
Est. primary completion 2027-12-31 · NCT04566380 · CT.gov ↗
What to watch
Phase 2Gastric CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07374250 · CT.gov ↗
What to watch
Phase 2Locally Advanced Gastric/Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT06766578 · CT.gov ↗
What to watch
2028 (17)
January 2028 (2)
Phase 3Pancreatic CancerNot yet recruiting
Est. primary completion 2028-01 · NCT06571461 · CT.gov ↗
What to watch
Phase 2Cholangiocarcinoma, Biliary Tract CancerNot yet recruiting
Est. primary completion 2028-01-01 · NCT07561775 · CT.gov ↗
What to watch
March 2028 (1)
Phase 2Intrahepatic Cholangiocarcinoma (Icc), Neoadjuvant TherapyRecruiting
Est. primary completion 2028-03-01 · NCT07847710 · CT.gov ↗
What to watch
April 2028 (4)
Phase 1/2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-04 · NCT07551778 · CT.gov ↗
What to watch
Phase 2Gastric CancerNot yet recruiting
Est. primary completion 2028-04-01 · NCT07515625 · CT.gov ↗
What to watch
Phase 2Gastric CancerRecruiting
Est. primary completion 2028-04-30 · NCT07556640 · CT.gov ↗
What to watch
Phase 2Gastric or Esophagogastric Junction AdenocarcinomaRecruiting
Est. primary completion 2028-04-30 · NCT07569068 · CT.gov ↗
What to watch
May 2028 (2)
Phase 2Gastric CancerRecruiting
Est. primary completion 2028-05-09 · NCT07621484 · CT.gov ↗
What to watch
Phase 2Gastric CancerRecruiting
Est. primary completion 2028-05-31 · NCT07464756 · CT.gov ↗
What to watch
June 2028 (1)
Phase 2Gastric CancerNot yet recruiting
Est. primary completion 2028-06 · NCT07685704 · CT.gov ↗
What to watch
July 2028 (1)
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2028-07-30 · NCT07243938 · CT.gov ↗
What to watch
August 2028 (1)
Phase 4Gastric CancerActive not recruiting
Est. primary completion 2028-08 · NCT07944664 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2Gastric CancerRecruiting
Est. primary completion 2028-09-30 · NCT07194005 · CT.gov ↗
What to watch
October 2028 (2)
Phase 2Biliary Tract Cancer (BTC), Surgery, RadiotherapyRecruiting
Est. primary completion 2028-10-08 · NCT07893392 · CT.gov ↗
What to watch
Phase 3Gastric CancerRecruiting
Est. primary completion 2028-10-30 · NCT07366528 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) AdenocarcinomaRecruiting
Est. primary completion 2028-11-30 · NCT07699939 · CT.gov ↗
What to watch
December 2028 (1)
Phase 2Gastric Adenocarcinoma and Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2028-12-30 · NCT07384234 · CT.gov ↗
What to watch
2029 (8)
February 2029 (2)
Phase 2Gastric CancerRecruiting
Est. primary completion 2029-02-20 · NCT07492615 · CT.gov ↗
What to watch
Phase 2Extrahepatic Cholangiocarcinoma and Gallbladder CarcinomaRecruiting
Est. primary completion 2029-02-28 · NCT07636824 · CT.gov ↗
What to watch
April 2029 (1)
Phase 2Gastric CancerRecruiting
Est. primary completion 2029-04-01 · NCT07007182 · CT.gov ↗
What to watch
July 2029 (1)
Phase 2Pancreatic Ductal Adenocarcinoma, Liver Neoplasms, Lung NeoplasmsNot yet recruiting
Est. primary completion 2029-07-31 · NCT07745790 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2Gastric CancerNot yet recruiting
Est. primary completion 2029-08-01 · NCT06881017 · CT.gov ↗
What to watch
September 2029 (2)
Phase 2Locally Advanced Gastric or Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2029-09 · NCT07828873 · CT.gov ↗
What to watch
Phase 2/3Biliary Tract Cancer, Second Line Treatment, Chemotherapy, Tyrosine Kinase InhibitorNot yet recruiting
Est. primary completion 2029-09-01 · NCT06662877 · CT.gov ↗
What to watch
December 2029 (1)
Phase 3Gastric CancerRecruiting
Est. primary completion 2029-12 · NCT07522151 · CT.gov ↗
What to watch
2030 (2)
June 2030 (1)
Phase 2CLDN18.2 Positive, Primary Gastric Adenocarcinoma, Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2030-06-30 · NCT07483567 · CT.gov ↗
What to watch
July 2030 (1)
Phase 2Cholangiocarcinoma, Biliary Tract Cancer (BTC)Not yet recruiting
Est. primary completion 2030-07-01 · NCT06903273 · CT.gov ↗
What to watch
2043 (1)
July 2043 (1)
Phase 2Colorectal CancerActive not recruiting
Est. primary completion 2043-07 · NCT02487992 · CT.gov ↗
What to watch

See the full readout calendar ↗